Table 3. Hypoglycemic, Anti-Hypertensive and Lipid Lowering Agents Which the Subjects Had Taken Before and After the Treatment With SGLT-2 Inhibitors.
| Medications | Pre-treatment (n = 50) | 1 month (n = 50) | 2 months (n = 41) | 3 months (n = 37) | 6 months (n = 23) |
|---|---|---|---|---|---|
| Biguanides | 41 | 39 | 35 | 30 | 19 |
| Thiazolidinediones | 17 | 17 | 16 | 14 | 8 |
| DPP-4 inhibitors | 26 | 24 | 21 | 18 | 10 |
| Sulfonylurea | 11 | 9 | 6 | 5 | 4 |
| α-GI | 6 | 7 | 7 | 6 | 2 |
| Glinides | 2 | 1 | 1 | 1 | 2 |
| GLP-1 analogues | 7 | 8 | 7 | 6 | 9 |
| Insulin | 15 | 14 | 12 | 11 | 5 |
| ACEi/ARB | 19 | 20 | 18 | 16 | 11 |
| Statins | 30 | 30 | 27 | 22 | 13 |
ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blockers; α-GI: alpha-glucosidase inhibitor; DPP-4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide 1.